John Mulder Drove Innovation In Diagnostics At Health 2.0 Conference
Health 2.0 Conference’s 2024 Dubai Edition Highlighted John Mulder As A Keynote Speaker
Dubai, UAE – May 24, 2025—The Winter Edition of the Health 2.0 Conference took place from December 3–5, 2024, at the InterContinental Dubai Festival City, Dubai. The global health conference welcomed a distinguished lineup of international healthcare speakers, professionals, and experts to share transformative ideas and breakthroughs redefining modern medicine. One of the standout voices at the event was John Mulder, CEO of Diagnoptics Technologies BV.
John Mulder’s insights into Advanced Glycation End Products (AGEs) have sparked important conversations around innovation in preventive healthcare and diagnostics. He is renowned for his strategic leadership and dedication to transforming the healthcare industry. As the driving force behind Diagnoptics, a pioneer in non-invasive diagnostics, he has successfully brought scientific breakthroughs to the forefront of clinical practice.
Under his leadership, the company developed the AGE Reader™, a state-of-the-art diagnostic device that non-invasively assesses AGE accumulation in 30 seconds. Diagnoptics introduced the AGE Reader mu in 2013, an affordable and accessible solution for family doctors and diabetologists. These technologies enable early detection of metabolic and vascular health risks, supporting a shift toward more proactive and personalized medical care.
John advocates for including AGEs as critical biomarkers, due to their significant role in conditions such as diabetes, cardiovascular disease, and impaired surgical recovery. He aims to support healthcare providers in adopting a more preventative, patient-centered approach to improve long-term outcomes. By connecting medical professionals with the latest scientific insights on AGEs, he aims to drive innovation in clinical practice.
During his keynote, titled “AGE Levels As A Novel Biomarker,” John explored the untapped diagnostic value of Advanced Glycation End-products. He emphasized how AGEs serve as early indicators of long-term damage caused by metabolic stress and chronic conditions. Drawing from his experience in innovation and implementation, he detailed how AGE testing could become a cornerstone of preventive medicine, allowing clinicians to make earlier, more informed decisions.
John Mulder’s participation in the health conference in Dubai shed light on the diagnostic potential of Advanced Glycation End-products (AGEs) in identifying chronic health risks, such as diabetes and cardiovascular disease. Through his contributions at the Health 2.0 Conference, John continues to bridge science and practice, empowering clinicians to adopt forward-thinking tools that improve patient outcomes and reshape the future of diagnostics.
About Health 2.0 Conference
The Health 2.0 Conference is a leading health summit that unites healthcare innovators, industry experts, policymakers, and investors to shape the future of healthcare. Spanning three immersive days, the event features insightful keynotes, expert panels, interactive discussions, startup showcases, and rich networking sessions. Strongly emphasizing digital health, telemedicine, mental well-being, and patient-centric innovation promotes cross-sector collaboration and forward-thinking dialogue. To learn more about the Health 2.0 Conference, please visit www.health2conf.com.
